All eyes are on agents that target the PD-1 pathway
Although it has been predicted that this will be a lean year for the approval and launch of blockbuster drugs this picture could all change if any of the anti-programmed death-1 (PD-1) antibodies under development make it to market.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter